ArticleScientific reports2025
Nomogram for the prediction of valproic acid induced platelet decline: a nested case-control study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Platelet decline is a frequent side effect of valproic acid, a medication commonly prescribed to prevent seizures in neurosurgical patients. However, the risk factors for valproic acid-associated platelet decline remain poorly understood, and it remains unknown whether linezolid or levetiracetam in combination with valproic acid is associated with thrombocytopenia, as both drugs could lead to the decrease in platelet count. This three center, retrospective nested case-control study aimed to develop a predictive model for the prediction of valproic acid-induced platelet decline in a cohort of 356 participants. Multivariate analyses identified advanced age (OR: 1.05; 95% CI 1.03-1.08; P = 0.030) and combination therapy between valproic acid and levetiracetam (OR: 3.03; 95% CI 1.43-6.65; P = 0.005) as independent risk factors, while a trough concentration of valproic acid below 100 μg/mL (OR: 0.41; 95% CI 0.24-0.69; P = 0.010) was an independent protective factor for platelet decline. A nomogram was developed based on these factors, demonstrating robust performance with an area under the curve value of 0.85 in the training cohort and 0.81 in the validation cohort. Calibration plots showed strong agreement between predicted and observed outcomes. This model provides a valuable tool for assessing the risk of platelet decline in valproic acid-treated neurosurgical patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.